论文信息 - Activity of Cabozantinib (XL184) in Hepatocellular Carcinoma (HCC) Patients: Results From a Phase 2 Randomized Discontinuation Trial (RDT) - 字舞流文

Activity of Cabozantinib (XL184) in Hepatocellular Carcinoma (HCC) Patients: Results From a Phase 2 Randomized Discontinuation Trial (RDT)

R. Kelley | C. Verslype | D. Ramies | W. Su | Xiao-dong Shen | E. Cutsem | A. Cohn | Yihua Lee | Tsai‐Sheng Yang